{"entity":{"id":"sotio","kind":"company","name":"SOTIO Biotech","aka":["SOTIO a.s.","SOTIO"],"tldr":"SOTIO is a Prague biotechnology company owned by the PPF group whose dendritic cell vaccine for prostate cancer failed its phase 3 trial in 2020, and which now develops an IL-15 superagonist and antibody-drug conjugates.","summary":"SOTIO Biotech, part of the PPF Group, ran the phase 3 VIABLE trial of DCVAC/PCa, an autologous dendritic cell immunotherapy added to docetaxel in metastatic castration-resistant prostate cancer, which did not improve survival when reported in 2020. Its pipeline now centres on nanrilkefusp alfa (SOT101), an IL-15 receptor superagonist tested with pembrolizumab, and antibody-drug conjugates from its BOXR and other platforms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sotio.com"},{"label":"ClinicalTrials.gov: trials led by SOTIO","url":"https://clinicaltrials.gov/search?lead=SOTIO"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":["immunotherapy","adcs"],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Prague","country":"CZ","companyType":"biotech","website":"https://www.sotio.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/sotio/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}]}}